MedPath

Fibroids and Infertility - a Study of the Significance of Removal of Fibroids With Regard to Endometrial Receptivity

Recruiting
Conditions
Leiomyoma, Uterine
Interventions
Procedure: Myomectomy per laparoscopy or laparotomy
Procedure: Transcervical resection of fibroids
Registration Number
NCT04426760
Lead Sponsor
Oslo University Hospital
Brief Summary

We aim to explore some of the molecular factors that reduce fertility for women with leiomyomas, taking into account leiomyoma location, size, number and vascularity. Tissue samples from the endometrium and leiomyomas will be obtained during the mid secretory phase before and 3-6 months after surgical excision for a comprehensive search for key molecular derangements.

Detailed Description

Baseline medical information and standard questionnaire to record symptoms are collected from all participants and a gynaecological examination and a 2D and 3D vaginal ultrasonography including saline infusion sonography (SIS), if indicated, are performed. Blood samples for the biobank for extraction of germ line DNA and for identification of possible biomarkers are taken.

The women with submucosal leiomyomas will undergo hysteroscopic myomectomy and the women with intramural leiomyomas will undergo myomectomy per laparoscopy or laparotomy.

For the participants with intramural leiomyomas and the fertile/infertile controls, endometrial samples are taken with an endometrial suction curette in an outpatient setting at day 19-23 of the menstrual cycle. The endometrial sampling in the group of women with submucosal leiomyomas is being done during the hysteroscopic removal of the leiomyoma, also at day 19-23 of the menstrual cycle.

3-6 months after surgery, cycle day 19-23, endometrial samples will be taken from the women who have undergone myomectomy and ultrasound examination is being performed. The women with submucosal leiomyomas will undergo a second look hysteroscopy

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
80
Inclusion Criteria
  • Age: 18 to 40 years
  • Presence of leiomyoma(s)
  • Regular menstrual cycle (28 +/- 7 days)
  • Having had at least 2 normal menstrual cycles after ending the treatment if previously treated with GnRH analogue
  • Signed informed consent
Exclusion Criteria
  • No treatment indication (no symptoms and/or no desire for fertility)
  • Contraindication for surgery
  • Known endometriosis
  • Known PCOS
  • Untreated hydrosalpinx
  • Malignancy; gynaecological or other location
  • Pre-malignant or malignant pap smear or endometrial biopsy
  • Hormonal treatment including ulipristal acetat and levonorgestrel intrauterine device last three months before inclusion in the study
  • Ongoing treatment with GnRH analogue
  • Pregnancy last 3 months
  • Ongoing lactation

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Women with intramural leiomyomasMyomectomy per laparoscopy or laparotomyWomen with intramural leiomyomas undergoing myomectomy
Women with submucosal leiomyoma(s)Transcervical resection of fibroidsWomen with submucosal leimyomas undergoing hysteroscopical removal of the leiomyoma
Primary Outcome Measures
NameTimeMethod
HOXA 10 expression3-6 months

Fold change of HOXA 10 Expression 3-6 months after myomectomy compared to pre-surgery Levels

Secondary Outcome Measures
NameTimeMethod
Expression of other molecular markers3-6 months

Fold change of other molecular markers than HOXA 10 of endometrial receptivity 3-6 months after myomectomy and compared to fertile/infertile controls

Vascular characteristics of leiomyomas3-6 months

Vascular characteristics of leiomyomas associated with endometrial changes

Genomic characteristics3-6 months

Genomic characteristics of leiomyomas associated with endometrial changes

Endometrial vascular pattern3-6 months

VI and FI of the endometrium and subendometrial myometrium of women with leimyomas 3-6 months after myomectomy and compared to fertile/infertile controls

Leiomyoma location3-6 months

Leiomyoma location associated with endometrial changes

Scar formation3-6 months

Scar/fibrosis/adhesion formation after myomectomy; macroscopically and histologically

Pregnancy2 years

Pregnancy and deliveries within 2 years after myomectomy.

Expression of molecular markers adjacent to the leiomyoma versus remote from the leiomyoma3-6 months

Difference in expression of molecular markers in endometrium adjacent to the leiomyoma compared to endometrium remote from the leiomyoma.

HOXA10 in endometrium of women with leiomyomas compared to fertile/infertile controls3-6 months

Difference in HOXA 10 expression in endometrium of women with leiomyomas compared to fertile/infertile controls

Leiomyoma size3-6 months

Leiomyomas size in centimeters associated with endometrial changes

Partially resected leiomyomas3-6 months

Alterations in molecular markers of endometrial receptivity after partially resected submucosal leiomyomas.

Submucosal leiomyomas versus intramural leiomyomas3-6 months

Difference in expression of molecular markers in endometrium of women with submucosal leiomyomas compared with endometrium in women with intramural leiomyomas.

Biomarkers in blood1 year

Biomarkers in blood related to leiomyomas and a possible correlation between certain biomarkers and reduced endometrial receptivity.

Trial Locations

Locations (1)

Oslo University Hospital

🇳🇴

Oslo, Norway

© Copyright 2025. All Rights Reserved by MedPath